Assembly Biosciences, Inc.: shareholders and insiders

ASMBNASDAQHealthcare · Pharmaceutical Preparations

Price

$22.50

November 19, 2026Market cap $461M

What Ploutos Investor adds for Assembly Biosciences

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 10 fiscal years, from 2016
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Insiders and their shares

Purchases and sales by officers and directors from Nov 19, 2025 to Nov 3, 2026, from their own Form 4 filings.

18 Form 4s

Bought on the market

–

nobody

Sold on the market

$252.3K

4 people

From Nov 19, 2025 to Nov 19, 2026, the days the chart shows. Change its range and the figures follow.

How the sales were made, as a share of their value

  • Under a set plan0%
  • The rest100%

By year

Insiders' open-market purchases (up) and sales (down), by value, since Nov 19, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.

2026·no buys·sold $252.3K by 4 people

  • 2025: no buys, no sales
  • 2026: no buys, sold $252.3K by 4 people
  • Nov 2, 2026Jeanette M BjorkquistPFO and PAO
    Kind
  • Nov 2, 2026Jeanette M BjorkquistPFO and PAO
    Kind
  • Nov 2, 2026Nicole S WhiteChief Manufacturing Officer
    Kind
  • Nov 2, 2026Nicole S WhiteChief Manufacturing Officer
    Kind
  • Nov 2, 2026Anuj GaggarChief Medical Officer
    Kind
  • Nov 2, 2026Anuj GaggarChief Medical Officer
    Kind
  • Nov 2, 2026Jason A OkazakiCEO and President
    Kind
  • Nov 2, 2026Jason A OkazakiCEO and President
    Kind
  • Oct 30, 2026Jeanette M BjorkquistPFO and PAO
    Kind
  • Oct 30, 2026Nicole S WhiteChief Manufacturing Officer
    Kind
  • Oct 30, 2026William E Delaney IVChief Scientific Officer
    Kind
  • Oct 30, 2026Anuj GaggarChief Medical Officer
    Kind
  • Oct 30, 2026Jason A OkazakiCEO and President
    Kind
  • Jun 17, 2026Jeanette M BjorkquistPFO and PAO
    Kind
  • May 26, 2026Gilead Sciences, Inc.
    Kind
  • Mar 29, 2026Anuj GaggarChief Medical Officer
    Kind
  • Mar 29, 2026Nicole S WhiteChief Manufacturing Officer
    Kind
  • Mar 29, 2026Jeanette M BjorkquistPFO and PAO
    Kind
  • Mar 29, 2026William E Delaney IVChief Scientific Officer
    Kind
  • Mar 29, 2026Jason A OkazakiCEO and President
    Kind
  • Mar 30, 2026Nicole S WhiteChief Manufacturing Officer
    Kind
  • Mar 30, 2026Nicole S WhiteChief Manufacturing Officer
    Kind
  • Mar 30, 2026Jeanette M BjorkquistPFO and PAO
    Kind
  • Mar 30, 2026Jeanette M BjorkquistPFO and PAO
    Kind

From the Form 4s insiders file with the SEC within two business days of each trade. Before May 27, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.

Insiders and their shares

Every buy and sale by ASMB's officers and directors from 2013 up to November 18, 2025, 13 more calendar years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 3 years.

Major holders (over 5%)

Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.

6 Holders over 5%1 On a 13DAug 14, 2026 Latest filing
  • Gilead Sciences
    Share of class25.1%
  • Commodore Capital LPwith 3 more persons
    Share of class9.90%
  • RA Capital Management, L.P.with 3 more persons
    Share of class9.50%
  • Farallon Capital Management, L.L.C.with 26 more persons
    Share of class8.10%
  • Paradigm BioCapital Advisors LPwith 3 more persons
    Share of class7.80%
  • JANUS HENDERSON GROUP Ltd.
    Share of class6.90%

What the holders on a 13D state as their purpose

From Item 4 of the filing, in the holder's own words. It is the intention the holder states, not something that happened.

  • Gilead Sciences25.1%From the filing of Aug 12, 2025

    Item 4 is amended to add the following immediately following the last paragraph: 2025 Securities Purchase Agreement and Warrants On August 8, 2025, pursuant to the 2025 Purchase Agreement, Gilead purchased from the Issuer 2,295,920 shares of Common Stock, the Series A Warrant, and the Series B Warrant, at a combined purchase price of $19.60 per share of Common Stock and accompanying one half of one Series A Warrant and one half of one Series B Warrant. The Series A Warrant is exercisable, in whole or in part, immediately at an exercise price of $21.60 per share and expires on the earlier of (i) 5:00 p.m. (New York City time) on August 11, 2030 and (ii) the date that is 30 days…

    From the filing of Aug 12, 2025
Fell to 5% or less (2)

Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.

  • Alexander Schornstein3.49%Aug 18, 202513G/A
  • Armistice Capital, LLC4.99%Feb 14, 202513G/A

From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.

Well-known managers

Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.

Sep 30, 2026 quarter end
  • Point72 (Cohen)
    In the quarter+34%
  • Millennium Mgmt (Englander)
    In the quarter+28%
  • Citadel Advisors (Griffin)
    In the quarter+277%
  • Renaissance Technologies
    In the quarter+184%

From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).

Short interest

How many of the company's shares have been sold borrowed and not yet bought back, twice a month.

On Oct 15, 2026, 14.2% of its shares outstanding were held short, +3.2% since the report before.

Shares held short
2.91M
14.2%
Since the report before2.82M on Sep 30, 2026
+3.2%
11.1
263.1K
More days to cover thanof 4,578 US-listed companies with enough volume
94%
Report date
Oct 15, 2026
  • Oct 31, 2023: Shares held short 785.3K
  • Nov 15, 2023: Shares held short 649.7K
  • Nov 30, 2023: Shares held short 528.0K
  • Dec 15, 2023: Shares held short 253.6K
  • Dec 29, 2023: Shares held short 201.0K
  • Jan 12, 2024: Shares held short 453.6K
  • Jan 31, 2024: Shares held short 353.3K
  • Feb 15, 2024: Shares held short 53.0K
  • Feb 29, 2024: Shares held short 19.6K
  • Mar 15, 2024: Shares held short 60.2K
  • Mar 28, 2024: Shares held short 42.6K
  • Apr 15, 2024: Shares held short 30.6K
  • Apr 30, 2024: Shares held short 24.8K
  • May 15, 2024: Shares held short 21.3K
  • May 31, 2024: Shares held short 18.3K
  • Jun 14, 2024: Shares held short 16.1K
  • Jun 28, 2024: Shares held short 18.9K
  • Jul 15, 2024: Shares held short 14.3K
  • Jul 31, 2024: Shares held short 12.3K
  • Aug 15, 2024: Shares held short 10.3K
  • Aug 30, 2024: Shares held short 16.2K
  • Sep 13, 2024: Shares held short 23.1K
  • Sep 30, 2024: Shares held short 17.8K
  • Oct 15, 2024: Shares held short 16.4K
  • Oct 31, 2024: Shares held short 7,949
  • Nov 15, 2024: Shares held short 11.5K
  • Nov 29, 2024: Shares held short 15.9K
  • Dec 13, 2024: Shares held short 13.3K
  • Dec 31, 2024: Shares held short 13.2K
  • Jan 15, 2025: Shares held short 14.4K
  • Jan 31, 2025: Shares held short 13.7K
  • Feb 14, 2025: Shares held short 17.2K
  • Feb 28, 2025: Shares held short 20.3K
  • Mar 14, 2025: Shares held short 20.7K
  • Mar 31, 2025: Shares held short 17.1K
  • Apr 15, 2025: Shares held short 18.6K
  • Apr 30, 2025: Shares held short 13.2K
  • May 15, 2025: Shares held short 26.3K
  • May 30, 2025: Shares held short 13.9K
  • Jun 13, 2025: Shares held short 16.6K
  • Jun 30, 2025: Shares held short 30.6K
  • Jul 15, 2025: Shares held short 30.6K
  • Jul 31, 2025: Shares held short 29.5K
  • Aug 15, 2025: Shares held short 530.9K
  • Aug 29, 2025: Shares held short 911.2K
  • Sep 15, 2025: Shares held short 1.07M
  • Sep 30, 2025: Shares held short 1.35M
  • Oct 15, 2025: Shares held short 1.53M
  • Oct 31, 2025: Shares held short 1.29M
  • Nov 14, 2025: Shares held short 1.31M
  • Nov 28, 2025: Shares held short 1.29M
  • Dec 15, 2025: Shares held short 1.37M
  • Dec 31, 2025: Shares held short 1.54M
  • Jan 15, 2026: Shares held short 1.57M
  • Jan 30, 2026: Shares held short 1.54M
  • Feb 13, 2026: Shares held short 1.49M
  • Feb 27, 2026: Shares held short 1.48M
  • Mar 13, 2026: Shares held short 1.52M
  • Mar 31, 2026: Shares held short 1.53M
  • Apr 15, 2026: Shares held short 1.53M
  • Apr 30, 2026: Shares held short 1.56M
  • May 15, 2026: Shares held short 1.54M
  • May 29, 2026: Shares held short 1.68M
  • Jun 15, 2026: Shares held short 1.87M
  • Jun 30, 2026: Shares held short 2.41M
  • Jul 15, 2026: Shares held short 2.31M
  • Jul 31, 2026: Shares held short 2.34M
  • Aug 14, 2026: Shares held short 2.31M
  • Aug 31, 2026: Shares held short 2.12M
  • Sep 15, 2026: Shares held short 2.10M
  • Sep 30, 2026: Shares held short 2.82M
  • Oct 15, 2026: Shares held short 2.91M

As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.

Short sales in daily trading58.6% of the shares in the last 14 sessions' reported trades were short sales.

In the last 14 sessions, 58.6% of the shares in the reported trades were short sales, against 57.2% in the 14 before.

Last 14 sessionsOct 30, 2026 – Nov 18, 2026
58.6%
The 14 beforeOct 12, 2026 – Oct 29, 2026
57.2%
Change
+1.4 pts
Short sales a dayon average, of 132.1K shares
77.5K
More than atof 3,656 US-listed companies, same days
79%
Median of alleight in ten from 34.4% to 63.7%
50.3%
  • Oct 12, 2026: Short sales 45.2%
  • Oct 13, 2026: Short sales 41.6%
  • Oct 14, 2026: Short sales 54.3%
  • Oct 15, 2026: Short sales 48%
  • Oct 16, 2026: Short sales 43.3%
  • Oct 19, 2026: Short sales 66.8%
  • Oct 20, 2026: Short sales 69.8%
  • Oct 21, 2026: Short sales 66.6%
  • Oct 22, 2026: Short sales 52.1%
  • Oct 23, 2026: Short sales 70.5%
  • Oct 26, 2026: Short sales 62.2%
  • Oct 27, 2026: Short sales 55.7%
  • Oct 28, 2026: Short sales 64.9%
  • Oct 29, 2026: Short sales 64.7%
  • Oct 30, 2026: Short sales 75%
  • Nov 2, 2026: Short sales 69.5%
  • Nov 3, 2026: Short sales 67%
  • Nov 4, 2026: Short sales 52.4%
  • Nov 5, 2026: Short sales 69.7%
  • Nov 6, 2026: Short sales 43.4%
  • Nov 9, 2026: Short sales 36.4%
  • Nov 10, 2026: Short sales 51.1%
  • Nov 11, 2026: Short sales 64.8%
  • Nov 12, 2026: Short sales 64.5%
  • Nov 13, 2026: Short sales 68.5%
  • Nov 16, 2026: Short sales 71.7%
  • Nov 17, 2026: Short sales 56.3%
  • Nov 18, 2026: Short sales 46.7%

This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.

What the insiders hold

The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.

6.13M Insiders' shares38.63% Of the company
  • Gilead Sciences, Inc.TenPercentOwner
    Directly4.98M
  • Alexander SchornsteinTenPercentOwner
    Directly728.1K
  • Jason A OkazakiCEO and President
    Directly195.5K
  • William E Delaney IVChief Scientific Officer
    Directly74.0K
  • Nicole S WhiteChief Manufacturing Officer
    Directly59.3K
  • Anuj GaggarChief Medical Officer
    Directly53.8K
  • John G McHutchisonDirector
    Directly18.3K
  • Jeanette M BjorkquistPFO and PAO
    Directly17.7K
  • Michael HoughtonDirector
    Directly–

A lower bound: it counts only the 9 officers and directors with a market trade since Nov 20, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.

The ETFs that hold it

Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.

7 ETFs holding it0.06% The largest weight (IWC)
  • IWCiShares Micro-Cap ETF
    Weight in the fund0.06%
  • IWNiShares Russell 2000 Value ETF
    Weight in the fund0.02%
  • VTWOVanguard Russell 2000 Index Fund
    Weight in the fund0.01%
  • IWMiShares Russell 2000 ETF
    Weight in the fund0.01%
  • VHTVanguard Health Care Index Fund
    Weight in the fund0.00%
  • VXFVanguard Extended Market Index Fund
    Weight in the fund0.00%
  • VTIVanguard Total Stock Market Index Fund
    Weight in the fund0.00%

7 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.

Institutional investors by quarter

Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.

93 Managers, Q2 2026$515M Value of their positions
  • Q3 2025: Managers 57
  • Q4 2025: Managers 69
  • Q1 2026: Managers 75
  • Q2 2026: Managers 93

Institutional investors by quarter

The fund managers holding ASMB, quarter by quarter, from Q3 2014 to Q2 2025, 44 more quarters

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 12 quarters.

Q2 2026: 93 managers held 18.75M shares, worth $515M. During the quarter 34 opened a position, 16 closed one, 33 added and 17 trimmed.

The largest holders, Q2 2026

  • Gilead Sciences
    In the quarter+10%
  • Farallon Capital Management
    In the quarter+31%
  • Paradigm Biocapital Advisors
    In the quarter+134%
  • Commodore Capital
    In the quarter+42%
  • Ra Capital Management
    In the quarter
  • Jupiter Topco
    In the quarter
  • BlackRock
    In the quarter+278%
  • Parkman Healthcare Partners
    In the quarter+75%
  • Vanguard Capital Management
    In the quarter+14%
  • Point72 (Cohen)
    In the quarter+34%

From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.

Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.

The full analysis

What do Assembly Biosciences's filings show?

Who buys and sells is one part of Assembly Biosciences's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about ASMB's shareholders

Didn't find what you were looking for?

Ask us
Have ASMB's insiders bought or sold?

From May 27, 2026 to Nov 3, 2026 Assembly Biosciences's insiders bought 0 and sold $238.3K of shares on the market. 0% of the sales were under set 10b5-1 plans.

Which well-known managers hold ASMB?

4 of the managers we track held the shares on Sep 30, 2026. The largest position was Point72 (Cohen)'s, worth $13M.

Is every insider transaction a purchase or a sale?

No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.